Share this video  

ESMO WCGIC 2021 | 1L NALIRIFOX in advanced or metastatic PDAC

Zev A. Wainberg, MD, Msc, UCLA School of Medicine, LA, CA, discusses findings of a Phase I/II study evaluating the safety and efficacy of first-line (1L) liposomal irinotecan + oxaliplatin + 5-fluorouracil + leucovorin (NALIRIFOX) in patients with pancreatic ductal adenocarcinoma (mPDAC). First-line NALIRIFOX for patients with locally advanced/mPDAC was generally manageable and tolerable, and a randomized, controlled Phase III study is underway. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.